Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genmab A/S stock logo
GMAB
Genmab A/S
$20.21
-0.2%
$21.29
$18.64
$31.88
$13.37B0.98897,314 shs1.81 million shs
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$131.25
+0.0%
$121.11
$63.30
$131.37
$13.96B0.691.32 million shs2.68 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$35.01
+3.7%
$36.38
$29.25
$170.47
$13.51B1.8612.56 million shs6.59 million shs
Zai Lab Limited stock logo
ZLAB
Zai Lab
$35.43
+0.2%
$28.80
$13.48
$37.99
$3.88B1.08749,282 shs451,496 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genmab A/S stock logo
GMAB
Genmab A/S
-7.83%-13.16%+6.63%-5.99%-36.05%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-0.01%0.00%+3.33%+56.46%+100.58%
Moderna, Inc. stock logo
MRNA
Moderna
-6.12%+11.16%+3.56%-21.23%-69.85%
Zai Lab Limited stock logo
ZLAB
Zai Lab
+1.90%+3.97%+28.41%+30.15%+76.66%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Genmab A/S stock logo
GMAB
Genmab A/S
3.9935 of 5 stars
4.43.00.00.02.40.03.1
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
3.6083 of 5 stars
2.23.00.04.52.91.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.2058 of 5 stars
4.01.00.04.62.12.50.6
Zai Lab Limited stock logo
ZLAB
Zai Lab
2.1079 of 5 stars
3.51.00.00.02.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genmab A/S stock logo
GMAB
Genmab A/S
2.77
Moderate Buy$41.33104.52% Upside
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.47
Hold$106.08-19.18% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$60.6373.18% Upside
Zai Lab Limited stock logo
ZLAB
Zai Lab
3.00
Buy$45.0327.11% Upside

Current Analyst Ratings Breakdown

Latest ZLAB, GMAB, ITCI, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/11/2025
Genmab A/S stock logo
GMAB
Genmab A/S
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$50.00 ➝ $45.00
3/11/2025
Genmab A/S stock logo
GMAB
Genmab A/S
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
3/7/2025
Zai Lab Limited stock logo
ZLAB
Zai Lab
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$55.00
3/4/2025
Zai Lab Limited stock logo
ZLAB
Zai Lab
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/3/2025
Zai Lab Limited stock logo
ZLAB
Zai Lab
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$29.00 ➝ $36.10
2/24/2025
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$140.00 ➝ $132.00
2/21/2025
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
2/19/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$96.00 ➝ $78.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$40.00 ➝ $40.00
2/18/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$111.00 ➝ $45.00
2/14/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$45.00
(Data available from 3/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genmab A/S stock logo
GMAB
Genmab A/S
$21.53B0.62$1.37 per share14.80$8.04 per share2.51
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$680.50M20.51N/AN/A$6.15 per share21.34
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B4.22N/AN/A$28.33 per share1.24
Zai Lab Limited stock logo
ZLAB
Zai Lab
$398.99M9.72N/AN/A$8.05 per share4.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genmab A/S stock logo
GMAB
Genmab A/S
$1.14B$1.7411.6111.352.6536.30%16.78%13.79%5/1/2025 (Estimated)
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$0.73N/A690.79N/A-14.07%-9.93%-8.38%5/6/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)
Zai Lab Limited stock logo
ZLAB
Zai Lab
-$334.62M-$2.59N/AN/AN/A-76.14%-36.97%-27.10%5/14/2025 (Estimated)

Latest ZLAB, GMAB, ITCI, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/27/2025Q4 2024
Zai Lab Limited stock logo
ZLAB
Zai Lab
-$0.61-$0.80-$0.19-$0.80$110.15 million$109.07 million
2/21/2025Q4 2024
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million
2/12/2025Q4 2024
Genmab A/S stock logo
GMAB
Genmab A/S
$0.28$0.57+$0.29$0.85$884.02 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genmab A/S stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Zai Lab Limited stock logo
ZLAB
Zai Lab
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genmab A/S stock logo
GMAB
Genmab A/S
N/A
5.25
5.24
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
7.66
7.51
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Zai Lab Limited stock logo
ZLAB
Zai Lab
N/A
3.01
2.87

Institutional Ownership

CompanyInstitutional Ownership
Genmab A/S stock logo
GMAB
Genmab A/S
7.07%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Zai Lab Limited stock logo
ZLAB
Zai Lab
41.65%

Insider Ownership

CompanyInsider Ownership
Genmab A/S stock logo
GMAB
Genmab A/S
1.54%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.60%
Moderna, Inc. stock logo
MRNA
Moderna
15.70%
Zai Lab Limited stock logo
ZLAB
Zai Lab
13.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genmab A/S stock logo
GMAB
Genmab A/S
2,204661.77 million651.58 millionOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
560106.33 million103.56 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600385.82 million324.40 millionOptionable
Zai Lab Limited stock logo
ZLAB
Zai Lab
2,175109.43 million94.24 millionOptionable

Recent News About These Companies

Zai Lab (ZLAB) Initiated with a Buy at Scotiabank
Zai Lab (NASDAQ:ZLAB) Coverage Initiated by Analysts at Scotiabank
Cantor Fitzgerald Comments on Zai Lab FY2025 Earnings
Zai Lab initiated with an Outperform at Scotiabank
Leerink Partnrs Predicts Zai Lab FY2026 Earnings
Zai Lab downgraded to Neutral from Buy at BofA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$20.21 -0.05 (-0.25%)
Closing price 04:00 PM Eastern
Extended Trading
$20.22 +0.01 (+0.05%)
As of 05:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Intra-Cellular Therapies stock logo

Intra-Cellular Therapies NASDAQ:ITCI

$131.25 +0.01 (+0.01%)
Closing price 04:00 PM Eastern
Extended Trading
$131.25 0.00 (0.00%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Moderna stock logo

Moderna NASDAQ:MRNA

$35.01 +1.25 (+3.70%)
Closing price 04:00 PM Eastern
Extended Trading
$35.18 +0.17 (+0.49%)
As of 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Zai Lab stock logo

Zai Lab NASDAQ:ZLAB

$35.43 +0.08 (+0.23%)
Closing price 04:00 PM Eastern
Extended Trading
$35.09 -0.34 (-0.96%)
As of 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.